How a specific protein affects blood vessel and immune cell interactions after COVID-19 infection
MLL1 drives collaborative leukocyte-endothelial cell signaling and thrombosis after coronavirus infection
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-11006251
This study is looking at how a protein called MLL1 affects the way immune cells and blood vessel cells work together after a coronavirus infection, with the goal of finding new ways to help people avoid serious problems like severe breathing issues from COVID-19.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11006251 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the MLL1 protein in the interactions between immune cells and blood vessel cells following infection with the coronavirus. It focuses on understanding how this protein contributes to severe complications like acute respiratory distress syndrome (ARDS) and other inflammatory responses. By examining the mechanisms of endothelial cell activation and the inflammatory response, the research aims to identify potential therapeutic targets to mitigate the harmful effects of COVID-19. Patients may benefit from insights gained into how to better manage or prevent severe outcomes related to COVID-19.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have experienced severe COVID-19 symptoms, particularly those with ARDS.
Not a fit: Patients who have not been infected with COVID-19 or those with mild symptoms may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients suffering from severe COVID-19 complications.
How similar studies have performed: Other research has shown promising results in understanding the inflammatory responses associated with COVID-19, suggesting that this approach could yield valuable insights.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PARCHMENT, NATHANIEL — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: PARCHMENT, NATHANIEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome